Radiocolloid in combination with methylene dye localization, rather than wire localization, is a preferred procedure for excisional biopsy of nonpalpable breast lesions

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

Wire localization (WL) is traditionally performed before excisional biopsy for patients with nonpalpable breast lesions, but it has several disadvantages.

Their current study examines whether the method of radiocolloid combined with methylene dye localization (RCML) has an advantage over WL.

Who Took Part

The study group was 2009, patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, women only.

From August 2006 to May 2009, 157 patients with nonpalpable breast lesions classified as BI-RADS category 5 were enrolled in their study.

Of the 157 patients, 78 were assigned to WL and 79 to RCML.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

The status of surgical margins, weight of specimens, length of incisions, and duration of operation were compared between these two groups.

What Was Measured

Topics PubMed links to this paper include Biopsy, Breast, Breast Neoplasms, Carcinoma, Ductal, Breast, Methylene Blue, Neoplasm Staging and Prognosis.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 2009, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Annals of surgical oncology), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.